[144] Charles River Laboratories International, Inc. SEC Filing
Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600. The shares represent part of outstanding common stock of 49,120,000 and an approximate sale date of 08/18/2025 on the NYSE. The filing shows the shares were acquired as Performance Stock Units on 01/27/2023 from Charles River Laboratories and that payment at sale is expected in cash. The filer previously sold 400 shares on 08/07/2025 for $59,991. The notice includes the customary attestation that the seller is unaware of undisclosed material adverse information.
Avviso Form 144 per Charles River Laboratories (CRL) segnala la proposta vendita di 800 azioni ordinarie tramite UBS Financial Services (Weehawken, NJ) per un valore di mercato complessivo di $125.600. Le azioni sono parte di un capitale sociale in circolazione di 49.120.000 e la data di vendita indicativa 猫 il 18/08/2025 sul NYSE. La comunicazione indica che le azioni sono state acquisite come Performance Stock Units il 27/01/2023 da Charles River Laboratories e che il pagamento alla vendita 猫 previsto in contanti. Il dichiarante aveva gi脿 venduto 400 azioni il 07/08/2025 per $59.991. L'avviso contiene la consueta attestazione secondo cui il venditore non 猫 a conoscenza di informazioni riservate rilevanti non divulgate.
Aviso Form 144 para Charles River Laboratories (CRL) comunica la propuesta de venta de 800 acciones ordinarias a trav茅s de UBS Financial Services (Weehawken, NJ) con un valor de mercado agregado de $125,600. Las acciones forman parte de un capital social en circulaci贸n de 49,120,000 y la fecha aproximada de venta es el 18/08/2025 en la NYSE. La presentaci贸n indica que las acciones se adquirieron como Performance Stock Units el 27/01/2023 de Charles River Laboratories y que el pago en la venta se espera en efectivo. El declarante vendi贸 anteriormente 400 acciones el 07/08/2025 por $59,991. El aviso incluye la habitual declaraci贸n de que el vendedor desconoce informaci贸n material adversa no divulgada.
Charles River Laboratories(CRL)鞐� 雽�頃� Form 144 韱奠電� UBS Financial Services(Weehawken, NJ)毳� 韱淀暣 氤错喌欤� 800欤�毳� 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滌灔臧�旃� $125,600鞐� 頃措嫻頃滊嫟瓿� 氚濏瀳瓿� 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 鞙犿喌 氤错喌欤� 齑濎垬 49,120,000欤�鞚� 鞚茧秬鞚措┌, NYSE鞐愳劀鞚� 鞓堨儊 毵る弰鞚检潃 2025-08-18鞛呺媹雼�. 氤搓碃靹滌棎 霐半ゴ氅� 鞚� 欤检嫕鞚� Performance Stock Units搿� 2023-01-27鞐� Charles River Laboratories搿滊秬韯� 旆摑霅橃棃瓿�, 毵る弰 鞁� 雽�旮堨潃 顺勱笀鞙茧 歆�旮夒悹 鞓堨爼鞛呺媹雼�. 鞝滌稖鞛愲姅 鞚挫爠鞐�
Avis Form 144 pour Charles River Laboratories (CRL) r茅v猫le la proposition de vente de 800 actions ordinaires via UBS Financial Services (Weehawken, NJ) pour une valeur de march茅 totale de $125,600. Ces actions font partie d'un capital social en circulation de 49,120,000 et la date approximative de vente sur le NYSE est le 18/08/2025. Le d茅p么t indique que les actions ont 茅t茅 acquises en tant que Performance Stock Units le 27/01/2023 aupr猫s de Charles River Laboratories et que le paiement 脿 la vente est pr茅vu en 别蝉辫猫肠别蝉. Le d茅clarant avait pr茅c茅demment vendu 400 actions le 07/08/2025 pour $59,991. L'avis inclut l'attestation habituelle selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Form 144-Mitteilung 蹿眉谤 Charles River Laboratories (CRL) legt den geplanten Verkauf von 800 Stammaktien 眉ber UBS Financial Services (Weehawken, NJ) mit einem gesamten Marktwert von $125.600 offen. Die Aktien sind Teil eines ausstehenden Stammkapitals von 49.120.000 und das voraussichtliche Verkaufsdatum an der NYSE ist der 18.08.2025. Die Einreichung weist aus, dass die Aktien am 27.01.2023 von Charles River Laboratories als Performance Stock Units erworben wurden und dass die Zahlung beim Verkauf voraussichtlich in Bargeld erfolgen wird. Der Einreicher hatte zuvor 400 Aktien am 07.08.2025 蹿眉谤 $59.991 verkauft. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offenbarten, wesentlichen nachteiligen Informationen bekannt sind.
- None.
- None.
Insights
TL;DR: Routine insider disclosure of planned sale of equity received as performance awards; transaction appears procedural, not material.
The Form 144 documents a proposed sale of 800 common shares by an insider via UBS, with shares acquired as Performance Stock Units on 01/27/2023. The disclosure is consistent with Rule 144 reporting requirements and includes a recent smaller sale of 400 shares on 08/07/2025 generating $59,991. There is no earnings, debt, or operational data in the filing to suggest a material change to the company鈥檚 fundamentals; the filing primarily notifies the market of an intended resale of restricted or control securities.
TL;DR: Compliance-focused filing showing adherence to resale notice rules; no governance red flags evident from the notice alone.
The document supplies required information: broker name, number of shares, acquisition date and nature (Performance Stock Unit), and a seller attestation about material information. The presence of a prior sale within the past three months is disclosed. Absent other disclosures in this form, there is no indication of insider trading policy breaches or undisclosed corporate events; this is a standard Rule 144 resale notice for regulatory transparency.
Avviso Form 144 per Charles River Laboratories (CRL) segnala la proposta vendita di 800 azioni ordinarie tramite UBS Financial Services (Weehawken, NJ) per un valore di mercato complessivo di $125.600. Le azioni sono parte di un capitale sociale in circolazione di 49.120.000 e la data di vendita indicativa 猫 il 18/08/2025 sul NYSE. La comunicazione indica che le azioni sono state acquisite come Performance Stock Units il 27/01/2023 da Charles River Laboratories e che il pagamento alla vendita 猫 previsto in contanti. Il dichiarante aveva gi脿 venduto 400 azioni il 07/08/2025 per $59.991. L'avviso contiene la consueta attestazione secondo cui il venditore non 猫 a conoscenza di informazioni riservate rilevanti non divulgate.
Aviso Form 144 para Charles River Laboratories (CRL) comunica la propuesta de venta de 800 acciones ordinarias a trav茅s de UBS Financial Services (Weehawken, NJ) con un valor de mercado agregado de $125,600. Las acciones forman parte de un capital social en circulaci贸n de 49,120,000 y la fecha aproximada de venta es el 18/08/2025 en la NYSE. La presentaci贸n indica que las acciones se adquirieron como Performance Stock Units el 27/01/2023 de Charles River Laboratories y que el pago en la venta se espera en efectivo. El declarante vendi贸 anteriormente 400 acciones el 07/08/2025 por $59,991. El aviso incluye la habitual declaraci贸n de que el vendedor desconoce informaci贸n material adversa no divulgada.
Charles River Laboratories(CRL)鞐� 雽�頃� Form 144 韱奠電� UBS Financial Services(Weehawken, NJ)毳� 韱淀暣 氤错喌欤� 800欤�毳� 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滌灔臧�旃� $125,600鞐� 頃措嫻頃滊嫟瓿� 氚濏瀳瓿� 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 鞙犿喌 氤错喌欤� 齑濎垬 49,120,000欤�鞚� 鞚茧秬鞚措┌, NYSE鞐愳劀鞚� 鞓堨儊 毵る弰鞚检潃 2025-08-18鞛呺媹雼�. 氤搓碃靹滌棎 霐半ゴ氅� 鞚� 欤检嫕鞚� Performance Stock Units搿� 2023-01-27鞐� Charles River Laboratories搿滊秬韯� 旆摑霅橃棃瓿�, 毵る弰 鞁� 雽�旮堨潃 顺勱笀鞙茧 歆�旮夒悹 鞓堨爼鞛呺媹雼�. 鞝滌稖鞛愲姅 鞚挫爠鞐�
Avis Form 144 pour Charles River Laboratories (CRL) r茅v猫le la proposition de vente de 800 actions ordinaires via UBS Financial Services (Weehawken, NJ) pour une valeur de march茅 totale de $125,600. Ces actions font partie d'un capital social en circulation de 49,120,000 et la date approximative de vente sur le NYSE est le 18/08/2025. Le d茅p么t indique que les actions ont 茅t茅 acquises en tant que Performance Stock Units le 27/01/2023 aupr猫s de Charles River Laboratories et que le paiement 脿 la vente est pr茅vu en 别蝉辫猫肠别蝉. Le d茅clarant avait pr茅c茅demment vendu 400 actions le 07/08/2025 pour $59,991. L'avis inclut l'attestation habituelle selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Form 144-Mitteilung 蹿眉谤 Charles River Laboratories (CRL) legt den geplanten Verkauf von 800 Stammaktien 眉ber UBS Financial Services (Weehawken, NJ) mit einem gesamten Marktwert von $125.600 offen. Die Aktien sind Teil eines ausstehenden Stammkapitals von 49.120.000 und das voraussichtliche Verkaufsdatum an der NYSE ist der 18.08.2025. Die Einreichung weist aus, dass die Aktien am 27.01.2023 von Charles River Laboratories als Performance Stock Units erworben wurden und dass die Zahlung beim Verkauf voraussichtlich in Bargeld erfolgen wird. Der Einreicher hatte zuvor 400 Aktien am 07.08.2025 蹿眉谤 $59.991 verkauft. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offenbarten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does the Form 144 filed for CRL disclose?
Who acquired the securities and how were they acquired?
Has the seller made recent share sales in the past three months?
Through which broker will the proposed sale be executed?
Does the filing state whether payment will be in cash?
